Syndax Pharmaceuticals Q1 2026 Earnings Call Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 01 2026
0mins
Source: seekingalpha
- Strong Sales Performance: Syndax Pharmaceuticals achieved over $100 million in combined sales of Revuforj and Niktimvo in Q1 2026, demonstrating robust demand for both medicines and advancing the company towards profitability.
- Revuforj Revenue Growth: Revuforj net revenue reached $49 million, significantly increasing the estimate of KMT2A patients able to receive potentially curative stem cell transplants to nearly 50%, up from the previous estimate of 33%, indicating improved treatment efficacy.
- Stable Niktimvo Performance: Niktimvo delivered $55 million in net revenue in Q1, reflecting consistent new patient starts despite natural attrition, suggesting strong ongoing market demand.
- Sufficient Funding: As of March 31, 2026, the company reported $352.1 million in cash, cash equivalents, and marketable securities, ensuring the ability to continue investing in its R&D and commercial priorities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNDX
Wall Street analysts forecast SNDX stock price to rise
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 19.040
Low
27.00
Averages
39.11
High
56.00
Current: 19.040
Low
27.00
Averages
39.11
High
56.00
About SNDX
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Revumenib Shows Promising Clinical Data in Acute Leukemia
- Clinical Trial Results: In newly diagnosed patients with NPM1m or KMT2Ar acute myeloid leukemia, the Phase 1 trial of Revumenib combined with intensive chemotherapy demonstrated a 97% CRc rate (34/35), indicating its potential to significantly improve patient outcomes.
- Real-World Study: The ROAR study focusing on relapsed/refractory NPM1m or KMT2Ar acute leukemia showed an overall response rate (ORR) of 82% (9/11) for Revumenib, highlighting its effectiveness and safety in clinical applications.
- Post-Transplant Efficacy: In the AUGMENT-101 trial, patients resuming Revumenib after hematopoietic stem cell transplantation exhibited a remarkable 1-year overall survival rate of 95%, showcasing its potential for maintaining efficacy post-transplant.
- Combination Therapy Benefits: The SAVE trial revealed an 88% ORR (37/42) for patients receiving Revumenib in combination with Venetoclax and Decitabine/Cedazuridine, underscoring its broad applicability and clinical value across various treatment regimens.
See More
Syndax Pharmaceuticals Issues $250M Convertible Senior Notes
- Financing Size: Syndax Pharmaceuticals has entered into privately negotiated agreements to issue $250 million in 2.25% convertible senior notes, expected to close on June 10, 2026, with net proceeds of approximately $243 million allocated for general corporate purposes.
- Bond Terms: The notes are senior unsecured obligations with a 2.25% interest rate, paying semiannual interest on June 15 and December 15, starting December 15, 2026, maturing on June 15, 2031, and convertible by noteholders before March 15, 2031.
- Market Reaction: Following the announcement of the bond issuance, Syndax's stock price rose 1.4% during pre-market trading on Thursday, indicating a positive market response to the company's financing strategy, potentially boosting investor confidence.
- R&D Investment: The company plans to use the proceeds to support research and development, commercialization activities, and business development, with an operational expense target of approximately $400 million for 2026, highlighting its strategic focus on new drug launches and market expansion.
See More
Syndax Releases Revuforj Data for Acute Leukemia Treatment
- Clinical Trial Results: Syndax Pharmaceuticals presented data on Revuforj (revumenib) at the 2026 ASCO annual meeting, demonstrating significant therapeutic potential in patients with acute leukemia and acute myeloid leukemia (AML) post-hematopoietic stem cell transplants (HSCT).
- Survival Rate Improvement: Analysis of 24 AML patients with NPM1 mutations revealed a 2-year overall survival rate of 90%, significantly higher than the standard care rate of 51%, indicating Revuforj's critical role in enhancing patient outcomes.
- Significantly Reduced Relapse Rates: The 1-year cumulative relapse rate was 0% in patients achieving first complete remission and 17% in those in second complete remission, contrasting sharply with historical rates of 12% and 40%, respectively, showcasing Revuforj's substantial advantages.
- Good Safety Profile: No significant toxicities were observed associated with Revuforj during the trials, further enhancing its appeal as a treatment option for acute leukemia while laying a solid foundation for future clinical applications.
See More
Syndax's Revuforj Showcases New Data at ASCO Meeting
- Clinical Trial Results: At the upcoming ASCO Annual Meeting, Syndax will present clinical data from 21 acute leukemia patients treated with Revuforj, demonstrating favorable overall survival and relapse rates, which could enhance the drug's acceptance in post-transplant maintenance therapy.
- Pharmacokinetic Features: The pharmacokinetic data of Revuforj will be highlighted, emphasizing its unique ability to be administered with commonly prescribed gastric acid reducers without compromising efficacy, which may improve patient adherence and strengthen market competitiveness.
- New Trial Designs: Syndax will showcase key trial designs for Revuforj in combination with varying intensities of chemotherapy, particularly for newly diagnosed patients with NPM1 mutations or KMT2A rearrangements, providing crucial evidence for future treatment protocols that could redefine standard care.
- Scientific Leadership: Syndax's strong presence at ASCO not only underscores its scientific leadership in menin inhibition but also reflects its deep commitment to advancing cancer care, likely attracting increased investor interest in its research pipeline.
See More
Revumenib Shows Promising Results in Acute Leukemia Treatment
- Clinical Data Highlights: Syndax Pharmaceuticals presented 12 abstracts on Revuforj (revumenib) at the EHA 2026 Congress, demonstrating strong clinical activity across acute leukemia subtypes, particularly KMT2Ar, NPM1m, and NUP98r, potentially transforming treatment paradigms.
- Efficacy and Tolerability: New real-world data show that revumenib, both as monotherapy and in combination, exhibits favorable tolerability and significant efficacy in acute leukemia patients, particularly in the post-transplant setting, supporting physician decision-making and enhancing confidence in ongoing clinical trials.
- Frontline and Relapse Data: The combination of revumenib with intensive chemotherapy shows up to 50% MRD negativity rates and significantly improved transplant success rates in newly diagnosed acute myeloid leukemia patients, indicating its potential in clinical applications.
- Scientific Leadership: Nick Botwood, Chief Medical Officer of Syndax, stated that these data underscore the company's scientific leadership in menin inhibition, with expectations to provide new treatment options for over 50% of acute myeloid leukemia patients.
See More
Syndax Pharmaceuticals Q1 2026 Earnings Call Highlights
- Strong Sales Performance: Syndax Pharmaceuticals achieved over $100 million in combined sales of Revuforj and Niktimvo in Q1 2026, demonstrating robust demand for both medicines and advancing the company towards profitability.
- Revuforj Revenue Growth: Revuforj net revenue reached $49 million, significantly increasing the estimate of KMT2A patients able to receive potentially curative stem cell transplants to nearly 50%, up from the previous estimate of 33%, indicating improved treatment efficacy.
- Stable Niktimvo Performance: Niktimvo delivered $55 million in net revenue in Q1, reflecting consistent new patient starts despite natural attrition, suggesting strong ongoing market demand.
- Sufficient Funding: As of March 31, 2026, the company reported $352.1 million in cash, cash equivalents, and marketable securities, ensuring the ability to continue investing in its R&D and commercial priorities.
See More
Revumenib Shows Promising Clinical Data in Acute Leukemia
- Clinical Trial Results: In newly diagnosed patients with NPM1m or KMT2Ar acute myeloid leukemia, the Phase 1 trial of Revumenib combined with intensive chemotherapy demonstrated a 97% CRc rate (34/35), indicating its potential to significantly improve patient outcomes.
- Real-World Study: The ROAR study focusing on relapsed/refractory NPM1m or KMT2Ar acute leukemia showed an overall response rate (ORR) of 82% (9/11) for Revumenib, highlighting its effectiveness and safety in clinical applications.
- Post-Transplant Efficacy: In the AUGMENT-101 trial, patients resuming Revumenib after hematopoietic stem cell transplantation exhibited a remarkable 1-year overall survival rate of 95%, showcasing its potential for maintaining efficacy post-transplant.
- Combination Therapy Benefits: The SAVE trial revealed an 88% ORR (37/42) for patients receiving Revumenib in combination with Venetoclax and Decitabine/Cedazuridine, underscoring its broad applicability and clinical value across various treatment regimens.
See More
Syndax Pharmaceuticals Issues $250M Convertible Senior Notes
- Financing Size: Syndax Pharmaceuticals has entered into privately negotiated agreements to issue $250 million in 2.25% convertible senior notes, expected to close on June 10, 2026, with net proceeds of approximately $243 million allocated for general corporate purposes.
- Bond Terms: The notes are senior unsecured obligations with a 2.25% interest rate, paying semiannual interest on June 15 and December 15, starting December 15, 2026, maturing on June 15, 2031, and convertible by noteholders before March 15, 2031.
- Market Reaction: Following the announcement of the bond issuance, Syndax's stock price rose 1.4% during pre-market trading on Thursday, indicating a positive market response to the company's financing strategy, potentially boosting investor confidence.
- R&D Investment: The company plans to use the proceeds to support research and development, commercialization activities, and business development, with an operational expense target of approximately $400 million for 2026, highlighting its strategic focus on new drug launches and market expansion.
See More
Syndax Releases Revuforj Data for Acute Leukemia Treatment
- Clinical Trial Results: Syndax Pharmaceuticals presented data on Revuforj (revumenib) at the 2026 ASCO annual meeting, demonstrating significant therapeutic potential in patients with acute leukemia and acute myeloid leukemia (AML) post-hematopoietic stem cell transplants (HSCT).
- Survival Rate Improvement: Analysis of 24 AML patients with NPM1 mutations revealed a 2-year overall survival rate of 90%, significantly higher than the standard care rate of 51%, indicating Revuforj's critical role in enhancing patient outcomes.
- Significantly Reduced Relapse Rates: The 1-year cumulative relapse rate was 0% in patients achieving first complete remission and 17% in those in second complete remission, contrasting sharply with historical rates of 12% and 40%, respectively, showcasing Revuforj's substantial advantages.
- Good Safety Profile: No significant toxicities were observed associated with Revuforj during the trials, further enhancing its appeal as a treatment option for acute leukemia while laying a solid foundation for future clinical applications.
See More
Syndax's Revuforj Showcases New Data at ASCO Meeting
- Clinical Trial Results: At the upcoming ASCO Annual Meeting, Syndax will present clinical data from 21 acute leukemia patients treated with Revuforj, demonstrating favorable overall survival and relapse rates, which could enhance the drug's acceptance in post-transplant maintenance therapy.
- Pharmacokinetic Features: The pharmacokinetic data of Revuforj will be highlighted, emphasizing its unique ability to be administered with commonly prescribed gastric acid reducers without compromising efficacy, which may improve patient adherence and strengthen market competitiveness.
- New Trial Designs: Syndax will showcase key trial designs for Revuforj in combination with varying intensities of chemotherapy, particularly for newly diagnosed patients with NPM1 mutations or KMT2A rearrangements, providing crucial evidence for future treatment protocols that could redefine standard care.
- Scientific Leadership: Syndax's strong presence at ASCO not only underscores its scientific leadership in menin inhibition but also reflects its deep commitment to advancing cancer care, likely attracting increased investor interest in its research pipeline.
See More
Revumenib Shows Promising Results in Acute Leukemia Treatment
- Clinical Data Highlights: Syndax Pharmaceuticals presented 12 abstracts on Revuforj (revumenib) at the EHA 2026 Congress, demonstrating strong clinical activity across acute leukemia subtypes, particularly KMT2Ar, NPM1m, and NUP98r, potentially transforming treatment paradigms.
- Efficacy and Tolerability: New real-world data show that revumenib, both as monotherapy and in combination, exhibits favorable tolerability and significant efficacy in acute leukemia patients, particularly in the post-transplant setting, supporting physician decision-making and enhancing confidence in ongoing clinical trials.
- Frontline and Relapse Data: The combination of revumenib with intensive chemotherapy shows up to 50% MRD negativity rates and significantly improved transplant success rates in newly diagnosed acute myeloid leukemia patients, indicating its potential in clinical applications.
- Scientific Leadership: Nick Botwood, Chief Medical Officer of Syndax, stated that these data underscore the company's scientific leadership in menin inhibition, with expectations to provide new treatment options for over 50% of acute myeloid leukemia patients.
See More
Syndax Pharmaceuticals Q1 2026 Earnings Call Highlights
- Strong Sales Performance: Syndax Pharmaceuticals achieved over $100 million in combined sales of Revuforj and Niktimvo in Q1 2026, demonstrating robust demand for both medicines and advancing the company towards profitability.
- Revuforj Revenue Growth: Revuforj net revenue reached $49 million, significantly increasing the estimate of KMT2A patients able to receive potentially curative stem cell transplants to nearly 50%, up from the previous estimate of 33%, indicating improved treatment efficacy.
- Stable Niktimvo Performance: Niktimvo delivered $55 million in net revenue in Q1, reflecting consistent new patient starts despite natural attrition, suggesting strong ongoing market demand.
- Sufficient Funding: As of March 31, 2026, the company reported $352.1 million in cash, cash equivalents, and marketable securities, ensuring the ability to continue investing in its R&D and commercial priorities.
See More
